Seqstant
Seqstant offers a comprehensive package for live analysis of pathogens, with a patent-pending adapter, user-friendly data uploader, and algorithms for real-time identification of pathogens, resistance genes, and quality metrics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | €1.8m | Seed | |
| Total Funding | 000k | ||
Related Content
Seqstant GmbH is a pioneering company in the field of metagenomic diagnostics, offering advanced solutions for laboratory information systems. The company's flagship product, LiveGene, is designed to provide comprehensive diagnostic results that can be seamlessly integrated into existing laboratory workflows. Seqstant operates primarily in the healthcare and biotechnology markets, serving clinical laboratories, research institutions, and healthcare providers. The business model revolves around the development, manufacturing, and distribution of its diagnostic software and services. Revenue is generated through the sale of software licenses, service subscriptions, and ongoing support contracts. The company has recently secured a seed investment of 1.8 million euros, which will be used to further market LiveGene and expand its operations. Seqstant is ISO 13485 certified, ensuring the highest standards in quality management for medical devices.
Keywords: metagenomic diagnostics, LiveGene, laboratory integration, ISO 13485, healthcare, biotechnology, clinical laboratories, software licenses, service subscriptions, quality management.